Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Vitamin K2 for the treatment of vascular injury in patients with chronic kidney disease.

Czekalski S, Pawlaczyk K.

Pol Arch Med Wewn. 2015;125(9):613-4. No abstract available.

2.

Novel markers of kidney injury in bipolar patients on long-term lithium treatment.

Rybakowski JK, Abramowicz M, Chłopocka-Wozniak M, Czekalski S.

Hum Psychopharmacol. 2013 Nov;28(6):615-8. doi: 10.1002/hup.2362.

PMID:
24519695
3.

The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.

Rybakowski JK, Abramowicz M, Szczepankiewicz A, Michalak M, Hauser J, Czekalski S.

Int J Bipolar Disord. 2013 Jun 20;1:8. doi: 10.1186/2194-7511-1-8. eCollection 2013.

4.

[The effect of long-term lithium treatment on kidney function].

Rybakowski J, Drogowska J, Abramowicz M, Chłopocka-Woźniak M, Czekalski S.

Psychiatr Pol. 2012 Jul-Aug;46(4):627-36. Review. Polish.

PMID:
23214164
5.

Screening for the markers of kidney damage in men and women on long-term lithium treatment.

Rybakowski JK, Abramowicz M, Drogowska J, Chłopocka-Woźniak M, Michalak M, Czekalski S.

Med Sci Monit. 2012 Nov;18(11):CR656-60.

6.

Pregnancy in diabetic woman with coexisting hypothyroidism, coronary artery disease and with early onset nephrotic syndrome--a case report.

Wender-Ozegowska E, Zawiejska A, Wanic-Kossowska M, Ozegowski S, Brazert J, Czekalski S.

Ginekol Pol. 2012 Apr;83(4):305-8.

PMID:
22712265
7.

Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis.

Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S.

Nephrol Dial Transplant. 2010 Dec;25(12):3948-56. doi: 10.1093/ndt/gfq310. Epub 2010 Jun 4.

PMID:
20525973
8.

Elevated urinary fibronectin excretion predicts poor outcome in patients with primary chronic glomerulonephritis.

Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S.

Nephron Clin Pract. 2010;116(1):c47-52. doi: 10.1159/000314550. Epub 2010 May 12.

PMID:
20484935
9.

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A; Epoetin Zeta Study Group.

Adv Ther. 2010 Feb;27(2):105-17. doi: 10.1007/s12325-010-0012-y. Epub 2010 Mar 30.

PMID:
20369312
10.

[Nephrological care in Wielkopolska-region of Poland in 2009--realization of the united idea].

Czekalski S.

Pol Merkur Lekarski. 2009 Jul;27(157):5-9. Polish.

PMID:
19650420
11.

Effects of bicarbonate/lactate dialysis solution on the inflammatory response of spontaneous peritonitis in rats undergoing chronic peritoneal dialysis.

Pawlaczyk K, Holmes CJ, Czekalski S, Breborowicz A, Lindholm B.

Blood Purif. 2009;28(3):200-8. doi: 10.1159/000230811. Epub 2009 Jul 31.

PMID:
19648739
12.

Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study.

Szklarek-Kubicka M, Fijałkowska-Morawska J, Zaremba-Drobnik D, Uciński A, Czekalski S, Nowicki M.

J Ren Nutr. 2009 Nov;19(6):487-93. doi: 10.1053/j.jrn.2009.05.007. Epub 2009 Jul 17.

PMID:
19616450
13.

The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?

Kubiak-Wlekły A, Perkowska-Ptasińska A, Olejniczak P, Rochowiak A, Kaczmarek E, Durlik M, Czekalski S, Niemir ZI.

Int J Biomed Sci. 2009 Mar;5(1):28-36.

14.

CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.

Oko A, Wyrwicz LS, Glyda M, Idasiak-Piechocka I, Bińczak-Kuleta A, Kaczmarczyk M, Drozd A, Ciechanowicz A, Czekalski S.

Ann Acad Med Stetin. 2009;55(2):22-6.

PMID:
20349607
15.

Effect of membrane permeability on survival of hemodialysis patients.

Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group.

J Am Soc Nephrol. 2009 Mar;20(3):645-54. doi: 10.1681/ASN.2008060590. Epub 2008 Dec 17.

16.

Early detection of chronic kidney disease: results of the PolNef study.

Król E, Rutkowski B, Czarniak P, Kraszewska E, Lizakowski S, Szubert R, Czekalski S, Sułowicz W, Wiecek A.

Am J Nephrol. 2009;29(3):264-73. doi: 10.1159/000158526. Epub 2008 Sep 23.

17.

Vascular endothelial growth factor in dialysate in relation to intensity of peritoneal inflammation.

Pawlaczyk K, Polubinska A, Numata N, Nakayama M, Pecoits-Filho R, Czekalski S, Lindholm B, Breborowicz A.

Int J Artif Organs. 2008 Jun;31(6):535-44.

PMID:
18609506
18.

Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.

Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 May;24(5):1407-15. doi: 10.1185/030079908X297402 . Epub 2008 Apr 4.

PMID:
18394266
19.

[Nephrotic syndrome in the elderly. Treatment of the nephrotic syndrome in the elderly (part II)].

Szmyt M, Niemir ZI, Czekalski S.

Pol Merkur Lekarski. 2007 Nov;23(137):391-4. Review. Polish.

PMID:
18361327
20.

[Nephrotic syndrome in the elderly. The most frequent causes of the nephrotic syndrome in the elderly (part I)].

Szmyt M, Niemir ZI, Czekalski S.

Pol Merkur Lekarski. 2007 Nov;23(137):386-90. Review. Polish.

PMID:
18361326
21.

"Treasure your exceptions": recent advances in molecular genetics of glomerular disease.

Ciechanowicz A, Brodkiewicz A, Bińczak-Kuleta A, Parczewski M, Czekalski S.

J Appl Genet. 2008;49(1):93-9. doi: 10.1007/BF03195253. Review.

PMID:
18263974
22.

The MPO Study: just a European HEMO Study or something very different?

Locatelli F, Gauly A, Czekalski S, Hannedouche T, Jacobson SH, Loureiro A, Martin-Malo A, Papadimitriou M, Passlick-Deetjen J, Ronco C, Vanholder R, Wizemann V; Membrane Permeability Outcome (MPO) Study Group.

Blood Purif. 2008;26(1):100-4. doi: 10.1159/000110574. Epub 2008 Jan 10. Review.

PMID:
18182806
23.

Effect of preload reduction on sonographic myocardial integrated backscatter.

Minczykowski A, Zaremba-Drobnik D, Pietrzak I, Czekalski S, Wysocki H.

J Clin Ultrasound. 2008 Mar-Apr;36(3):157-65.

PMID:
18088055
24.

[Hypotonia in renal failure patients undergoing dialysis therapy].

Wanic-Kossowska M, Czekalski S.

Pol Arch Med Wewn. 2007 Apr;117(4):58-63. Review. Polish.

25.

The effect of clodronate on bone mineral density and serum osteocalcin in postmenopausal women with osteopenia - a prospective, randomized, placebo-controlled study.

Napierała K, Miazgowski T, Hoszowski K, Bieńkowska R, Lorenc R, Czekalski S.

Ortop Traumatol Rehabil. 2006 Aug 31;8(4):430-4.

PMID:
17597688
26.

[Pathophysiological and clinical significance of microalbuminuria].

Czekalski S.

Pol Arch Med Wewn. 2006 Aug;116(2):731-5. Review. Polish. No abstract available.

PMID:
17424916
27.

Anemia treatment with darbepoetin alpha in pregnant female with chronic renal failure: report of two cases.

Sobiło-Jarek L, Popowska-Drojecka J, Muszytowski M, Wanic-Kossowska M, Kobelski M, Czekalski S.

Adv Med Sci. 2006;51:309-11.

PMID:
17357331
28.

[Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].

Wanic-Kossowska M, Tykarski A, Kobelski M, Czekalski S.

Pol Arch Med Wewn. 2006 Jul;116(1):663-70. Polish.

PMID:
17340973
29.

Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients.

Chrzanowska M, Kurzawski M, Droździk M, Mazik M, Oko A, Czekalski S.

Pharmacol Rep. 2006 Nov-Dec;58(6):973-8.

30.

[Inherited reduced number of nephrons versus primary arterial hypertension].

Czekalski S, Oko A, Pawlaczyk K.

Pol Merkur Lekarski. 2006 Aug;21(122):120-2; discussion 123-4. Review. Polish.

PMID:
17144093
31.

Development of renal replacement therapy in Poland.

Rutkowski B, Czekalski S, Lao M, Kokot F.

J Nephrol. 2006 May-Jun;19 Suppl 10:S159-64.

PMID:
16874731
32.

The history of nephrology in Poland.

Czekalski S, Rutkowski B.

J Nephrol. 2006 May-Jun;19 Suppl 10:S150-8.

PMID:
16874730
33.

[Vascular stiffness in chronic renal failure patients treated by hemodialysis].

Posadzy-Małaczyńska A, Wanic-Kossowska M, Tykarski A, Czekalski S, Głuszek J, Kosch M.

Pol Arch Med Wewn. 2005 Nov;114(5):1072-8. Polish.

PMID:
16789505
34.

[Cardiac troponin I (cTnl) serum concentration in patients with chronic renal failure treated by hemodialysis].

Wanic-Kossowska M, Kobelski M, Pawliczak E, Kozioł L, Czekalski S.

Pol Arch Med Wewn. 2003 Nov;110(5):1309-16. Polish.

PMID:
16737001
35.

[Heart rate variability in patients with chronic renal failure treated by hemodialysis].

Wanic-Kossowska M, Guzik P, Lehman P, Czekalski S.

Pol Arch Med Wewn. 2005 Sep;114(3):855-61. Polish.

PMID:
16708559
36.

[Progress in clarification of the pathogenesis of primary arterial hypertension].

Czekalski S, Ciechanowicz A.

Przegl Lek. 2005;62 Suppl 2:26-9. Review. Polish.

PMID:
16623114
37.

[Uraemic toxins and cardiovascular diseases].

Oko A, Pawlaczyk K, Czekalski S.

Przegl Lek. 2005;62 Suppl 2:7-10. Review. Polish.

PMID:
16623109
38.

[Early diagnosis of renal diseases--preliminary results from the pilot study PolNef].

Król E, Rutkowski B, Czekalski S, Sułowicz W, Wiecek A, Lizakowski S, Czarniak P, Szubert R, Karczewska-Maksymienko L, Orlikowska M, Kraszewska E, Magdoń R.

Przegl Lek. 2005;62(7):690-3. Polish.

PMID:
16463703
39.

Diabetic nephropathy and cardiovascular diseases.

Czekalski S.

Rocz Akad Med Bialymst. 2005;50:122-5. Review.

PMID:
16358950
40.

Arterial hypertension due to perirenal and subcapsular hematoma induced by renal percutaneous biopsy.

Wanic-Kossowska M, Kobelski M, Oko A, Czekałski S.

Int Urol Nephrol. 2005;37(1):141-3.

PMID:
16132777
41.

[Ciprofloxacin-induced acute non-oliguric renal failure in patient with chronic glomerulonephritis].

Paszkowska M, Niemir ZI, Nowak A, Czekalski S.

Wiad Lek. 2005;58(1-2):131-3. Polish.

PMID:
15991567
42.

[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management].

Czekalski S.

Pol Arch Med Wewn. 2004 Oct;112 Spec No:65-9. Polish.

PMID:
15669203
43.
44.

[The role of platelet-derived growth factor A (PDGF-A) in hypertension and renal diseases. Part 2: a role of PDGF-A in kidney diseases].

Miller-Kasprzak E, Niemir ZI, Czekalski S.

Pol Merkur Lekarski. 2004 Apr;16(94):403-5. Review. Polish.

PMID:
15517944
45.
46.

[Hypercalciuria with severe hypocalcaemia in association with distal renal tubular acidosis--case report and differential diagnostics].

Paszkowska M, Niemir ZI, Chudek J, Czekalski S.

Pol Arch Med Wewn. 2004 Jun;111(6):715-9. Polish.

PMID:
15508795
47.

[Promoter variants of aldosterone synthase gene (CYP11B2) and salt-sensitivity of blood pressure].

Wrona A, Widecka K, Adler G, Czekalski S, Ciechanowicz A.

Pol Arch Med Wewn. 2004 Feb;111(2):191-7. Polish.

PMID:
15230231
48.

[Epidemiology of kidney diseases in Poland--pilot study (PolNef)].

Rutkowski B, Czekalski S, Sułowicz W, Wiecek A, Król E, Szubert R, Kraszewska E.

Przegl Lek. 2004;61(1):22-4. Polish.

PMID:
15230101
49.

The in situ expression of interleukin-8 in the normal human kidney and in different morphological forms of glomerulonephritis.

Niemir ZI, Stein H, Ciechanowicz A, Olejniczak P, Dworacki G, Ritz E, Waldherr R, Czekalski S.

Am J Kidney Dis. 2004 Jun;43(6):983-98.

PMID:
15168378
50.

[Chronic renal insufficiency (part II)--current methods of slowing down disease progression].

Czekalski S, Oko A, Pawlaczyk K, Idasiak-Piechocka I.

Pol Arch Med Wewn. 2004 Jan;111(1):97-103. Review. Polish. No abstract available.

PMID:
15088429

Supplemental Content

Loading ...
Support Center